Background: Outcomes of tailoring statin-type based on solute carrier organic anion transporterfamily member 1B1 ( SLCO1B1)pharmacogenetic toxicity information on patient, provider, and pharmacological outcomes are unknown.
Methods: The trial randomized 159 patients not taking statins because of prior statin myalgia 1:1 to receiving SLCO1B1 GIST (Genotype Informed Statin Therapy) versus usual care (UC) and followed for up to 8 months. The UC arm received their SLCO1B1 results post-trial.
Technical advances are being made in many areas of biotechnology and genetics that are facilitating the detection of doping in sport. These improvements have been catalyzed by the need to counter the ever-increasing sophistication of the community of athletes and their retinues who are intent on the illicit use of physical, pharmacological and genetic tools and methods to enhance athletic performance, in contravention of established international ethical and legal standards and of international treaty. The methods described in this article present a partial and general picture of only some of these advances.
View Article and Find Full Text PDFBackground: Gene-environment studies demonstrate variability in nutrient requirements depending upon individual variations in genes affecting nutrient metabolism and transport. This study investigated whether the inclusion of genetic information to personalize a patient's diet (nutrigenetics) could improve long term weight management.
Methods: Patients with a history of failures at weight loss were offered a nutrigenetic test screening 24 variants in 19 genes involved in metabolism.